<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref24">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Byrn</surname>
    <given-names>R. A.</given-names>
   </name>
   <name>
    <surname>Jones</surname>
    <given-names>S. M.</given-names>
   </name>
   <name>
    <surname>Bennett</surname>
    <given-names>H. B.</given-names>
   </name>
   <name>
    <surname>Bral</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Clark</surname>
    <given-names>M. P.</given-names>
   </name>
   <name>
    <surname>Jacobs</surname>
    <given-names>M. D.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2015</year>). 
  <article-title>Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit</article-title>. 
  <source>Antimicrob. Agents Chemother.</source>
  <volume>59</volume>, 
  <fpage>1569</fpage>â€“
  <lpage>1582</lpage>. 
  <pub-id pub-id-type="doi">10.1128/AAC.04623-14</pub-id>, PMID: 
  <?supplied-pmid 25547360?>
  <pub-id pub-id-type="pmid">25547360</pub-id>
 </mixed-citation>
</ref>
